Coherus BioSciences (CHRS) - Quarterly EPS earnings growth

Official company branding of Coherus BioSciences, Inc. (CHRS)

Coherus Biosciences (CHRS) develops innovative oncology drugs and biosimilars, balancing fierce competition with premium pricing. The quarterly earnings per share trend clearly demonstrates revenue volatility, with the current figure standing at 16.90. Its status as the sole approved PD-1 inhibitor for rare carcinomas strengthens the firm's position, while the expansion of its ecosystem through AI solutions and insurance coverage ensures a steady capture of market share.

Coherus BioSciences Inc. (CHRS) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 11/17/2026

Analytical breakdowns for Coherus Biosciences

- market value and analyst target forecast:
Fundamental company analysis:coherus.com, CHRS
Manufactured product of Coherus Biosciences

Regulator-approved biosimilars and oncology drugs provide Coherus Biosciences (CHRS) with fundamental stability. This indicator measures the dynamics of net earnings per share, reflecting the actual speed of capital generation. By analyzing the trajectory of quarterly EPS growth, an investor determines the intensity of business scaling. Sharp spikes in the line may indicate temporary factors rather than systemic growth, allowing one to avoid overpaying for the asset ahead of a potential correction.

Analysis of competing companies

Incyte Corporation (INCY) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share growth for the last 12 months HUTCHMED Corp|NUVB (nuvationbio.com) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months dayonebio.com (DAWN)|Year-over-year earnings per share growth for the last twelve months Monopar Corp (MNPR)|INBX - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months I-Mab Inc. IMAB|Fennec - Year-over-year earnings per share growth for the last twelve months|HRTX - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Nuvectis Pharma, Inc.|CRBP: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Cardiff Oncology, Inc. CRDF|Year-over-year net earnings per share growth for the last 12 months BYSI|Earnings per share growth in annualized terms for the last twelve months BioAtla BCAB|Year-over-year net earnings per share growth for the last 12 months LIXT (Lixte Biotechnology)|CTXR (Citius Pharma) - Year-over-year earnings per one share growth for the last 12 months|Cellectar Biosciences - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months BLRX (BioLineRx)|Can-Fite BioPharma, Ltd. - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months APRE (aprea.com)|KZIA: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Silexion (SLXN)|Year-over-year earnings per share growth for the last twelve months nucana.com|CMRX: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth CYCC|Quarterly EPS earnings growth G1 Therapeutics Inc. (GTHX)|Year-over-year earnings per share growth for the last twelve months Kronos Bio Corp KRON|KTRA (Kintara Therapeutics, Inc.) - Year-over-year net earnings per share trend for the last twelve months|ONCT: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months Portage Biotech Inc